| 1 | regardless | 5,186 |
| 2 | irrespective | 2,575 |
| 3 | complaining | 202 |
| 4 | irrespectively | 33 |
| 5 | inspite | 30 |
| 6 | 5–17 | 4 |
| 7 | internet-databases | 3 |
| 8 | macroscopy | 3 |
| 9 | most/all | 3 |
| 10 | 'method | 2 |
| 11 | 'shortness | 2 |
| 12 | 1/12th | 2 |
| 13 | 14,144 | 2 |
| 14 | 21,943 | 2 |
| 15 | 5,081 | 2 |
| 16 | 50g | 2 |
| 17 | 6-18years | 2 |
| 18 | 6892 | 2 |
| 19 | fractionation/conversion | 2 |
| 20 | non-adequacy | 2 |
| 21 | non-attainment | 2 |
| 22 | non-expressor | 2 |
| 23 | optimation | 2 |
| 24 | perusal | 2 |
| 25 | porokeratosis | 2 |
| 26 | rapid-amplification | 2 |
| 27 | type/duration | 2 |
| 28 | type/number | 2 |
| 29 | vitalization | 2 |
| 30 | ''ease | 1 |
| 31 | 'capable | 1 |
| 32 | 'flora | 1 |
| 33 | 'ingredients | 1 |
| 34 | 'locus | 1 |
| 35 | 'outbursts | 1 |
| 36 | 'place | 1 |
| 37 | 'portrayal | 1 |
| 38 | 'positioning | 1 |
| 39 | 'relabeling | 1 |
| 40 | 'stiffness | 1 |
| 41 | 0.73g/100ml | 1 |
| 42 | 1-aryl-2-hydrazonoimidazolidines | 1 |
| 43 | 1/375,000 | 1 |
| 44 | 11,103 | 1 |
| 45 | 117.31mg/kg | 1 |
| 46 | 128,569 | 1 |
| 47 | 13,868 | 1 |
| 48 | 150µl | 1 |
| 49 | 166,4g | 1 |
| 50 | 17-epoxide | 1 |
| 51 | 181-200 | 1 |
| 52 | 19,1 | 1 |
| 53 | 2,158 | 1 |
| 54 | 2,329 | 1 |
| 55 | 2,356 | 1 |
| 56 | 2-exacerbation | 1 |
| 57 | 2000meq | 1 |
| 58 | 2007-issue | 1 |
| 59 | 201-240 | 1 |
| 60 | 21,3g | 1 |
| 61 | 21.1g/l | 1 |
| 62 | 24-recalls | 1 |
| 63 | 25-35min | 1 |
| 64 | 26.7kbp | 1 |
| 65 | 279-347 | 1 |
| 66 | 3.3g/l | 1 |
| 67 | 30-50μm | 1 |
| 68 | 35.9±4.3kg | 1 |
| 69 | 3688.15tons | 1 |
| 70 | 36±3.9weeks | 1 |
| 71 | 3incidences | 1 |
| 72 | 3′-utr | 1 |
| 73 | 4'-truncation | 1 |
| 74 | 4-5cm | 1 |
| 75 | 4.1g | 1 |
| 76 | 47.2mg/l | 1 |
| 77 | 5-cycles | 1 |
| 78 | 50/86 | 1 |
| 79 | 53percent | 1 |
| 80 | 63g | 1 |
| 81 | 67/189 | 1 |
| 82 | 7,789 | 1 |
| 83 | 7,903 | 1 |
| 84 | 7.8-9.3mg/kg | 1 |
| 85 | 73.8g/l | 1 |
| 86 | 74.0g/l | 1 |
| 87 | 7554 | 1 |
| 88 | 761-960 | 1 |
| 89 | 7670 | 1 |
| 90 | 8,110 | 1 |
| 91 | 8337 | 1 |
| 92 | 84.3/ | 1 |
| 93 | 8446 | 1 |
| 94 | 86mg | 1 |
| 95 | 9000kg | 1 |
| 96 | 9285 | 1 |
| 97 | a-fifth | 1 |
| 98 | a2-type | 1 |
| 99 | ab-block | 1 |
| 100 | aba-hypersensitivity | 1 |
| 101 | abstinance | 1 |
| 102 | acceptability•feasibility | 1 |
| 103 | acrts | 1 |
| 104 | acrys | 1 |
| 105 | adcs-activities | 1 |
| 106 | airrs | 1 |
| 107 | aminohydroxylation | 1 |
| 108 | aminooxygenation | 1 |
| 109 | andpresence | 1 |
| 110 | astatination | 1 |
| 111 | audio-taping | 1 |
| 112 | aα-chain | 1 |
| 113 | backpull | 1 |
| 114 | base/lack | 1 |
| 115 | bio-fermentation | 1 |
| 116 | bromoaminocyclization | 1 |
| 117 | but-regardless | 1 |
| 118 | catalyzer | 1 |
| 119 | cc₅₀ | 1 |
| 120 | chemotherapy-irrespective | 1 |
| 121 | clelopeptide | 1 |
| 122 | clinicians'perceptions | 1 |
| 123 | co-encapsulation | 1 |
| 124 | co-engagement | 1 |
| 125 | co-generation | 1 |
| 126 | codetection | 1 |
| 127 | colority | 1 |
| 128 | commemorations | 1 |
| 129 | consisitng | 1 |
| 130 | continuity/coordination | 1 |
| 131 | coselection/coresistance | 1 |
| 132 | countess | 1 |
| 133 | cyclization/hydrolysis | 1 |
| 134 | cys163 | 1 |
| 135 | cytotoxicyty | 1 |
| 136 | d-efficiencies | 1 |
| 137 | d-enantiomers | 1 |
| 138 | deficiency-weakness | 1 |
| 139 | deionization | 1 |
| 140 | depolarization-induced-activation | 1 |
| 141 | dichloroimination | 1 |
| 142 | distortion/defragmentation | 1 |
| 143 | distractability | 1 |
| 144 | driving-pressures | 1 |
| 145 | duration/sustainability | 1 |
| 146 | ease/pain | 1 |
| 147 | ecg-signs | 1 |
| 148 | echo-structure | 1 |
| 149 | efforts.improvement | 1 |
| 150 | embellishment | 1 |
| 151 | endo-factor | 1 |
| 152 | event-prevention | 1 |
| 153 | existence/absence | 1 |
| 154 | explicit-pairing | 1 |
| 155 | fine-mappings | 1 |
| 156 | firestorms | 1 |
| 157 | fixed-doses | 1 |
| 158 | floppiness | 1 |
| 159 | fluidisation | 1 |
| 160 | fluxionality | 1 |
| 161 | follow-up.most | 1 |
| 162 | follow-up/duration | 1 |
| 163 | friedrich-schiller-university | 1 |
| 164 | frostnip | 1 |
| 165 | gallocatechins | 1 |
| 166 | glencoe | 1 |
| 167 | gnments | 1 |
| 168 | h-permeability | 1 |
| 169 | hap25 | 1 |
| 170 | hepatocyte-toxicity | 1 |
| 171 | hepatotoxicokinetics | 1 |
| 172 | hospitalization/treatment | 1 |
| 173 | humboldt-university | 1 |
| 174 | hyperhemoglobinemia | 1 |
| 175 | ii-meta-analysis | 1 |
| 176 | imbrium | 1 |
| 177 | in12 | 1 |
| 178 | inconformity | 1 |
| 179 | indemed | 1 |
| 180 | independenty | 1 |
| 181 | inefficacity | 1 |
| 182 | inheritence | 1 |
| 183 | initiation/extinction | 1 |
| 184 | intensity-dose | 1 |
| 185 | isiweb | 1 |
| 186 | kenya-site | 1 |
| 187 | key-points | 1 |
| 188 | l4,5 | 1 |
| 189 | l=dianion | 1 |
| 190 | ld50/60 | 1 |
| 191 | leclerc | 1 |
| 192 | legth | 1 |
| 193 | levo-isomer | 1 |
| 194 | linelist | 1 |
| 195 | lings | 1 |
| 196 | low-concentrations | 1 |
| 197 | m1-/m2-polarization | 1 |
| 198 | marites | 1 |
| 199 | measurament | 1 |
| 200 | membrane-coverage | 1 |
| 201 | metadatabase | 1 |
| 202 | micro-areas | 1 |
| 203 | midsummers | 1 |
| 204 | mirnaomes | 1 |
| 205 | misportrayal | 1 |
| 206 | modes/durations | 1 |
| 207 | mohltccourtesy | 1 |
| 208 | mono-deamidation | 1 |
| 209 | monoglucosylation | 1 |
| 210 | monoparesis | 1 |
| 211 | mounding | 1 |
| 212 | multi-glycoside | 1 |
| 213 | non-consumer | 1 |
| 214 | non-containment | 1 |
| 215 | non-convergence | 1 |
| 216 | non-preparation | 1 |
| 217 | non-respect | 1 |
| 218 | nonhomogeneity | 1 |
| 219 | nonnecessity | 1 |
| 220 | nonsecretion | 1 |
| 221 | ntelopeptides | 1 |
| 222 | number/size/wetness | 1 |
| 223 | number/type | 1 |
| 224 | ofdiabetes | 1 |
| 225 | omni-rating | 1 |
| 226 | omnipresent-source | 1 |
| 227 | onslaught | 1 |
| 228 | onychodystrophia | 1 |
| 229 | over-burdening | 1 |
| 230 | over-suppression | 1 |
| 231 | overevaluation | 1 |
| 232 | overparameterization | 1 |
| 233 | paling/darkening | 1 |
| 234 | pcr-tests | 1 |
| 235 | peack | 1 |
| 236 | perfectionism/intolerance | 1 |
| 237 | performance-assessment | 1 |
| 238 | phase-disturbance | 1 |
| 239 | phosphorylation/degradation | 1 |
| 240 | photostabilities | 1 |
| 241 | point-to-point-model | 1 |
| 242 | polyphyly | 1 |
| 243 | post-addition | 1 |
| 244 | post-mini-hlm/release | 1 |
| 245 | pre-curing | 1 |
| 246 | precision/vagueness | 1 |
| 247 | presence/augmentation | 1 |
| 248 | prewashing | 1 |
| 249 | primarly | 1 |
| 250 | privation | 1 |
| 251 | proctoring | 1 |
| 252 | qantification | 1 |
| 253 | quality/availability | 1 |
| 254 | radix,4 | 1 |
| 255 | rarefiction | 1 |
| 256 | raucousness | 1 |
| 257 | re-conduct | 1 |
| 258 | re-ordering | 1 |
| 259 | recently-'free | 1 |
| 260 | receptor-activator | 1 |
| 261 | recordal | 1 |
| 262 | relaxation/quality | 1 |
| 263 | reperforation | 1 |
| 264 | resident-months | 1 |
| 265 | respectively.none | 1 |
| 266 | respectively.relief | 1 |
| 267 | reversible-inhibitor | 1 |
| 268 | rootbarks | 1 |
| 269 | rs2472300 | 1 |
| 270 | ru-contamination | 1 |
| 271 | rupsingh | 1 |
| 272 | sapienza-university | 1 |
| 273 | scarring/reorganization | 1 |
| 274 | sci//web | 1 |
| 275 | secession | 1 |
| 276 | sedimentations | 1 |
| 277 | selection/accumulation | 1 |
| 278 | selection/spread | 1 |
| 279 | self-destabilization | 1 |
| 280 | self-homeostasis | 1 |
| 281 | semiquantify | 1 |
| 282 | sero-discordance | 1 |
| 283 | shaltout | 1 |
| 284 | sheri-kashmir-institute | 1 |
| 285 | shorter-terms | 1 |
| 286 | six-compound-libraries | 1 |
| 287 | size/amount | 1 |
| 288 | sleight | 1 |
| 289 | sorness | 1 |
| 290 | stage/size | 1 |
| 291 | stimulant/depressant | 1 |
| 292 | stretching-type | 1 |
| 293 | structure/distribution | 1 |
| 294 | studied-length | 1 |
| 295 | sub-syndromes | 1 |
| 296 | sublevels | 1 |
| 297 | subtrates | 1 |
| 298 | sunphotometer | 1 |
| 299 | supershifts | 1 |
| 300 | synthesis/breakdown | 1 |
| 301 | systematizations | 1 |
| 302 | t2*-mapping | 1 |
| 303 | t4=end | 1 |
| 304 | tetrahydropyranylation | 1 |
| 305 | themetaregister | 1 |
| 306 | thermo-application | 1 |
| 307 | time-variation | 1 |
| 308 | time/number | 1 |
| 309 | tissue-inhibitor | 1 |
| 310 | tnp-haptenation | 1 |
| 311 | tory | 1 |
| 312 | type/periodicity | 1 |
| 313 | type/stage | 1 |
| 314 | underidentification | 1 |
| 315 | underinvolvement | 1 |
| 316 | v234i | 1 |
| 317 | veloycity | 1 |
| 318 | vels | 1 |
| 319 | withsensitivity | 1 |
| 320 | world-wide.three-quarters | 1 |
| 321 | wrapping/dressing | 1 |
| 322 | year-month | 1 |
| 323 | zimmer/university | 1 |
| 324 | ~4weeks | 1 |
| 325 | α1c-subunit | 1 |
| 326 | β-acetoxylation | 1 |
| 327 | γseop | 1 |
| 328 | “weight | 1 |
| 329 | ⅓ | 1 |
| 1 | ''ease | 1 |
| 2 | 'capable | 1 |
| 3 | 'flora | 1 |
| 4 | 'ingredients | 1 |
| 5 | 'locus | 1 |
| 6 | 'method | 2 |
| 7 | 'outbursts | 1 |
| 8 | 'place | 1 |
| 9 | 'portrayal | 1 |
| 10 | 'positioning | 1 |
| 11 | 'relabeling | 1 |
| 12 | 'shortness | 2 |
| 13 | 'stiffness | 1 |
| 14 | 0.73g/100ml | 1 |
| 15 | 1-aryl-2-hydrazonoimidazolidines | 1 |
| 16 | 1/12th | 2 |
| 17 | 1/375,000 | 1 |
| 18 | 11,103 | 1 |
| 19 | 117.31mg/kg | 1 |
| 20 | 128,569 | 1 |
| 21 | 13,868 | 1 |
| 22 | 14,144 | 2 |
| 23 | 150µl | 1 |
| 24 | 166,4g | 1 |
| 25 | 17-epoxide | 1 |
| 26 | 181-200 | 1 |
| 27 | 19,1 | 1 |
| 28 | 2,158 | 1 |
| 29 | 2,329 | 1 |
| 30 | 2,356 | 1 |
| 31 | 2-exacerbation | 1 |
| 32 | 2000meq | 1 |
| 33 | 2007-issue | 1 |
| 34 | 201-240 | 1 |
| 35 | 21,3g | 1 |
| 36 | 21,943 | 2 |
| 37 | 21.1g/l | 1 |
| 38 | 24-recalls | 1 |
| 39 | 25-35min | 1 |
| 40 | 26.7kbp | 1 |
| 41 | 279-347 | 1 |
| 42 | 3.3g/l | 1 |
| 43 | 30-50μm | 1 |
| 44 | 35.9±4.3kg | 1 |
| 45 | 3688.15tons | 1 |
| 46 | 36±3.9weeks | 1 |
| 47 | 3incidences | 1 |
| 48 | 3′-utr | 1 |
| 49 | 4'-truncation | 1 |
| 50 | 4-5cm | 1 |
| 51 | 4.1g | 1 |
| 52 | 47.2mg/l | 1 |
| 53 | 5,081 | 2 |
| 54 | 5-cycles | 1 |
| 55 | 50/86 | 1 |
| 56 | 50g | 2 |
| 57 | 53percent | 1 |
| 58 | 5–17 | 4 |
| 59 | 6-18years | 2 |
| 60 | 63g | 1 |
| 61 | 67/189 | 1 |
| 62 | 6892 | 2 |
| 63 | 7,789 | 1 |
| 64 | 7,903 | 1 |
| 65 | 7.8-9.3mg/kg | 1 |
| 66 | 73.8g/l | 1 |
| 67 | 74.0g/l | 1 |
| 68 | 7554 | 1 |
| 69 | 761-960 | 1 |
| 70 | 7670 | 1 |
| 71 | 8,110 | 1 |
| 72 | 8337 | 1 |
| 73 | 84.3/ | 1 |
| 74 | 8446 | 1 |
| 75 | 86mg | 1 |
| 76 | 9000kg | 1 |
| 77 | 9285 | 1 |
| 78 | a-fifth | 1 |
| 79 | a2-type | 1 |
| 80 | ab-block | 1 |
| 81 | aba-hypersensitivity | 1 |
| 82 | abstinance | 1 |
| 83 | acceptability•feasibility | 1 |
| 84 | acrts | 1 |
| 85 | acrys | 1 |
| 86 | adcs-activities | 1 |
| 87 | airrs | 1 |
| 88 | aminohydroxylation | 1 |
| 89 | aminooxygenation | 1 |
| 90 | andpresence | 1 |
| 91 | astatination | 1 |
| 92 | audio-taping | 1 |
| 93 | aα-chain | 1 |
| 94 | backpull | 1 |
| 95 | base/lack | 1 |
| 96 | bio-fermentation | 1 |
| 97 | bromoaminocyclization | 1 |
| 98 | but-regardless | 1 |
| 99 | catalyzer | 1 |
| 100 | cc₅₀ | 1 |
| 101 | chemotherapy-irrespective | 1 |
| 102 | clelopeptide | 1 |
| 103 | clinicians'perceptions | 1 |
| 104 | co-encapsulation | 1 |
| 105 | co-engagement | 1 |
| 106 | co-generation | 1 |
| 107 | codetection | 1 |
| 108 | colority | 1 |
| 109 | commemorations | 1 |
| 110 | complaining | 202 |
| 111 | consisitng | 1 |
| 112 | continuity/coordination | 1 |
| 113 | coselection/coresistance | 1 |
| 114 | countess | 1 |
| 115 | cyclization/hydrolysis | 1 |
| 116 | cys163 | 1 |
| 117 | cytotoxicyty | 1 |
| 118 | d-efficiencies | 1 |
| 119 | d-enantiomers | 1 |
| 120 | deficiency-weakness | 1 |
| 121 | deionization | 1 |
| 122 | depolarization-induced-activation | 1 |
| 123 | dichloroimination | 1 |
| 124 | distortion/defragmentation | 1 |
| 125 | distractability | 1 |
| 126 | driving-pressures | 1 |
| 127 | duration/sustainability | 1 |
| 128 | ease/pain | 1 |
| 129 | ecg-signs | 1 |
| 130 | echo-structure | 1 |
| 131 | efforts.improvement | 1 |
| 132 | embellishment | 1 |
| 133 | endo-factor | 1 |
| 134 | event-prevention | 1 |
| 135 | existence/absence | 1 |
| 136 | explicit-pairing | 1 |
| 137 | fine-mappings | 1 |
| 138 | firestorms | 1 |
| 139 | fixed-doses | 1 |
| 140 | floppiness | 1 |
| 141 | fluidisation | 1 |
| 142 | fluxionality | 1 |
| 143 | follow-up.most | 1 |
| 144 | follow-up/duration | 1 |
| 145 | fractionation/conversion | 2 |
| 146 | friedrich-schiller-university | 1 |
| 147 | frostnip | 1 |
| 148 | gallocatechins | 1 |
| 149 | glencoe | 1 |
| 150 | gnments | 1 |
| 151 | h-permeability | 1 |
| 152 | hap25 | 1 |
| 153 | hepatocyte-toxicity | 1 |
| 154 | hepatotoxicokinetics | 1 |
| 155 | hospitalization/treatment | 1 |
| 156 | humboldt-university | 1 |
| 157 | hyperhemoglobinemia | 1 |
| 158 | ii-meta-analysis | 1 |
| 159 | imbrium | 1 |
| 160 | in12 | 1 |
| 161 | inconformity | 1 |
| 162 | indemed | 1 |
| 163 | independenty | 1 |
| 164 | inefficacity | 1 |
| 165 | inheritence | 1 |
| 166 | initiation/extinction | 1 |
| 167 | inspite | 30 |
| 168 | intensity-dose | 1 |
| 169 | internet-databases | 3 |
| 170 | irrespective | 2,575 |
| 171 | irrespectively | 33 |
| 172 | isiweb | 1 |
| 173 | kenya-site | 1 |
| 174 | key-points | 1 |
| 175 | l4,5 | 1 |
| 176 | l=dianion | 1 |
| 177 | ld50/60 | 1 |
| 178 | leclerc | 1 |
| 179 | legth | 1 |
| 180 | levo-isomer | 1 |
| 181 | linelist | 1 |
| 182 | lings | 1 |
| 183 | low-concentrations | 1 |
| 184 | m1-/m2-polarization | 1 |
| 185 | macroscopy | 3 |
| 186 | marites | 1 |
| 187 | measurament | 1 |
| 188 | membrane-coverage | 1 |
| 189 | metadatabase | 1 |
| 190 | micro-areas | 1 |
| 191 | midsummers | 1 |
| 192 | mirnaomes | 1 |
| 193 | misportrayal | 1 |
| 194 | modes/durations | 1 |
| 195 | mohltccourtesy | 1 |
| 196 | mono-deamidation | 1 |
| 197 | monoglucosylation | 1 |
| 198 | monoparesis | 1 |
| 199 | most/all | 3 |
| 200 | mounding | 1 |
| 201 | multi-glycoside | 1 |
| 202 | non-adequacy | 2 |
| 203 | non-attainment | 2 |
| 204 | non-consumer | 1 |
| 205 | non-containment | 1 |
| 206 | non-convergence | 1 |
| 207 | non-expressor | 2 |
| 208 | non-preparation | 1 |
| 209 | non-respect | 1 |
| 210 | nonhomogeneity | 1 |
| 211 | nonnecessity | 1 |
| 212 | nonsecretion | 1 |
| 213 | ntelopeptides | 1 |
| 214 | number/size/wetness | 1 |
| 215 | number/type | 1 |
| 216 | ofdiabetes | 1 |
| 217 | omni-rating | 1 |
| 218 | omnipresent-source | 1 |
| 219 | onslaught | 1 |
| 220 | onychodystrophia | 1 |
| 221 | optimation | 2 |
| 222 | over-burdening | 1 |
| 223 | over-suppression | 1 |
| 224 | overevaluation | 1 |
| 225 | overparameterization | 1 |
| 226 | paling/darkening | 1 |
| 227 | pcr-tests | 1 |
| 228 | peack | 1 |
| 229 | perfectionism/intolerance | 1 |
| 230 | performance-assessment | 1 |
| 231 | perusal | 2 |
| 232 | phase-disturbance | 1 |
| 233 | phosphorylation/degradation | 1 |
| 234 | photostabilities | 1 |
| 235 | point-to-point-model | 1 |
| 236 | polyphyly | 1 |
| 237 | porokeratosis | 2 |
| 238 | post-addition | 1 |
| 239 | post-mini-hlm/release | 1 |
| 240 | pre-curing | 1 |
| 241 | precision/vagueness | 1 |
| 242 | presence/augmentation | 1 |
| 243 | prewashing | 1 |
| 244 | primarly | 1 |
| 245 | privation | 1 |
| 246 | proctoring | 1 |
| 247 | qantification | 1 |
| 248 | quality/availability | 1 |
| 249 | radix,4 | 1 |
| 250 | rapid-amplification | 2 |
| 251 | rarefiction | 1 |
| 252 | raucousness | 1 |
| 253 | re-conduct | 1 |
| 254 | re-ordering | 1 |
| 255 | recently-'free | 1 |
| 256 | receptor-activator | 1 |
| 257 | recordal | 1 |
| 258 | regardless | 5,186 |
| 259 | relaxation/quality | 1 |
| 260 | reperforation | 1 |
| 261 | resident-months | 1 |
| 262 | respectively.none | 1 |
| 263 | respectively.relief | 1 |
| 264 | reversible-inhibitor | 1 |
| 265 | rootbarks | 1 |
| 266 | rs2472300 | 1 |
| 267 | ru-contamination | 1 |
| 268 | rupsingh | 1 |
| 269 | sapienza-university | 1 |
| 270 | scarring/reorganization | 1 |
| 271 | sci//web | 1 |
| 272 | secession | 1 |
| 273 | sedimentations | 1 |
| 274 | selection/accumulation | 1 |
| 275 | selection/spread | 1 |
| 276 | self-destabilization | 1 |
| 277 | self-homeostasis | 1 |
| 278 | semiquantify | 1 |
| 279 | sero-discordance | 1 |
| 280 | shaltout | 1 |
| 281 | sheri-kashmir-institute | 1 |
| 282 | shorter-terms | 1 |
| 283 | six-compound-libraries | 1 |
| 284 | size/amount | 1 |
| 285 | sleight | 1 |
| 286 | sorness | 1 |
| 287 | stage/size | 1 |
| 288 | stimulant/depressant | 1 |
| 289 | stretching-type | 1 |
| 290 | structure/distribution | 1 |
| 291 | studied-length | 1 |
| 292 | sub-syndromes | 1 |
| 293 | sublevels | 1 |
| 294 | subtrates | 1 |
| 295 | sunphotometer | 1 |
| 296 | supershifts | 1 |
| 297 | synthesis/breakdown | 1 |
| 298 | systematizations | 1 |
| 299 | t2*-mapping | 1 |
| 300 | t4=end | 1 |
| 301 | tetrahydropyranylation | 1 |
| 302 | themetaregister | 1 |
| 303 | thermo-application | 1 |
| 304 | time-variation | 1 |
| 305 | time/number | 1 |
| 306 | tissue-inhibitor | 1 |
| 307 | tnp-haptenation | 1 |
| 308 | tory | 1 |
| 309 | type/duration | 2 |
| 310 | type/number | 2 |
| 311 | type/periodicity | 1 |
| 312 | type/stage | 1 |
| 313 | underidentification | 1 |
| 314 | underinvolvement | 1 |
| 315 | v234i | 1 |
| 316 | veloycity | 1 |
| 317 | vels | 1 |
| 318 | vitalization | 2 |
| 319 | withsensitivity | 1 |
| 320 | world-wide.three-quarters | 1 |
| 321 | wrapping/dressing | 1 |
| 322 | year-month | 1 |
| 323 | zimmer/university | 1 |
| 324 | ~4weeks | 1 |
| 325 | α1c-subunit | 1 |
| 326 | β-acetoxylation | 1 |
| 327 | γseop | 1 |
| 328 | “weight | 1 |
| 329 | ⅓ | 1 |
| 1 | 84.3/ | 1 |
| 2 | 1/375,000 | 1 |
| 3 | 181-200 | 1 |
| 4 | rs2472300 | 1 |
| 5 | 8,110 | 1 |
| 6 | 201-240 | 1 |
| 7 | ld50/60 | 1 |
| 8 | 761-960 | 1 |
| 9 | 7670 | 1 |
| 10 | 19,1 | 1 |
| 11 | 5,081 | 2 |
| 12 | in12 | 1 |
| 13 | 6892 | 2 |
| 14 | 11,103 | 1 |
| 15 | 7,903 | 1 |
| 16 | 21,943 | 2 |
| 17 | cys163 | 1 |
| 18 | radix,4 | 1 |
| 19 | 14,144 | 2 |
| 20 | 7554 | 1 |
| 21 | l4,5 | 1 |
| 22 | hap25 | 1 |
| 23 | 9285 | 1 |
| 24 | 8446 | 1 |
| 25 | 2,356 | 1 |
| 26 | 50/86 | 1 |
| 27 | 5–17 | 4 |
| 28 | 8337 | 1 |
| 29 | 279-347 | 1 |
| 30 | 2,158 | 1 |
| 31 | 13,868 | 1 |
| 32 | 2,329 | 1 |
| 33 | 128,569 | 1 |
| 34 | 67/189 | 1 |
| 35 | 7,789 | 1 |
| 36 | onychodystrophia | 1 |
| 37 | hyperhemoglobinemia | 1 |
| 38 | 'flora | 1 |
| 39 | sci//web | 1 |
| 40 | isiweb | 1 |
| 41 | leclerc | 1 |
| 42 | selection/spread | 1 |
| 43 | indemed | 1 |
| 44 | t4=end | 1 |
| 45 | 'method | 2 |
| 46 | 'place | 1 |
| 47 | phase-disturbance | 1 |
| 48 | sero-discordance | 1 |
| 49 | abstinance | 1 |
| 50 | perfectionism/intolerance | 1 |
| 51 | coselection/coresistance | 1 |
| 52 | non-convergence | 1 |
| 53 | existence/absence | 1 |
| 54 | andpresence | 1 |
| 55 | inheritence | 1 |
| 56 | omnipresent-source | 1 |
| 57 | multi-glycoside | 1 |
| 58 | clelopeptide | 1 |
| 59 | 17-epoxide | 1 |
| 60 | recently-'free | 1 |
| 61 | membrane-coverage | 1 |
| 62 | type/stage | 1 |
| 63 | 'capable | 1 |
| 64 | respectively.none | 1 |
| 65 | glencoe | 1 |
| 66 | a2-type | 1 |
| 67 | stretching-type | 1 |
| 68 | number/type | 1 |
| 69 | echo-structure | 1 |
| 70 | metadatabase | 1 |
| 71 | ''ease | 1 |
| 72 | post-mini-hlm/release | 1 |
| 73 | intensity-dose | 1 |
| 74 | inspite | 30 |
| 75 | kenya-site | 1 |
| 76 | sheri-kashmir-institute | 1 |
| 77 | 2007-issue | 1 |
| 78 | irrespective | 2,575 |
| 79 | chemotherapy-irrespective | 1 |
| 80 | stage/size | 1 |
| 81 | respectively.relief | 1 |
| 82 | 50g | 2 |
| 83 | 4.1g | 1 |
| 84 | 21,3g | 1 |
| 85 | 63g | 1 |
| 86 | 166,4g | 1 |
| 87 | 117.31mg/kg | 1 |
| 88 | 7.8-9.3mg/kg | 1 |
| 89 | 9000kg | 1 |
| 90 | 35.9±4.3kg | 1 |
| 91 | 86mg | 1 |
| 92 | mounding | 1 |
| 93 | prewashing | 1 |
| 94 | 'relabeling | 1 |
| 95 | over-burdening | 1 |
| 96 | paling/darkening | 1 |
| 97 | complaining | 202 |
| 98 | 'positioning | 1 |
| 99 | audio-taping | 1 |
| 100 | t2*-mapping | 1 |
| 101 | re-ordering | 1 |
| 102 | explicit-pairing | 1 |
| 103 | proctoring | 1 |
| 104 | pre-curing | 1 |
| 105 | wrapping/dressing | 1 |
| 106 | omni-rating | 1 |
| 107 | consisitng | 1 |
| 108 | rupsingh | 1 |
| 109 | 1/12th | 2 |
| 110 | a-fifth | 1 |
| 111 | legth | 1 |
| 112 | studied-length | 1 |
| 113 | year-month | 1 |
| 114 | v234i | 1 |
| 115 | peack | 1 |
| 116 | base/lack | 1 |
| 117 | ab-block | 1 |
| 118 | 74.0g/l | 1 |
| 119 | 21.1g/l | 1 |
| 120 | 3.3g/l | 1 |
| 121 | 73.8g/l | 1 |
| 122 | 47.2mg/l | 1 |
| 123 | recordal | 1 |
| 124 | perusal | 2 |
| 125 | 'portrayal | 1 |
| 126 | misportrayal | 1 |
| 127 | point-to-point-model | 1 |
| 128 | most/all | 3 |
| 129 | backpull | 1 |
| 130 | 0.73g/100ml | 1 |
| 131 | 150µl | 1 |
| 132 | 4-5cm | 1 |
| 133 | imbrium | 1 |
| 134 | 30-50μm | 1 |
| 135 | aα-chain | 1 |
| 136 | ease/pain | 1 |
| 137 | 25-35min | 1 |
| 138 | l=dianion | 1 |
| 139 | fractionation/conversion | 2 |
| 140 | secession | 1 |
| 141 | over-suppression | 1 |
| 142 | 2-exacerbation | 1 |
| 143 | rapid-amplification | 2 |
| 144 | qantification | 1 |
| 145 | underidentification | 1 |
| 146 | thermo-application | 1 |
| 147 | 4'-truncation | 1 |
| 148 | phosphorylation/degradation | 1 |
| 149 | mono-deamidation | 1 |
| 150 | time-variation | 1 |
| 151 | selection/accumulation | 1 |
| 152 | co-encapsulation | 1 |
| 153 | tetrahydropyranylation | 1 |
| 154 | monoglucosylation | 1 |
| 155 | aminohydroxylation | 1 |
| 156 | β-acetoxylation | 1 |
| 157 | optimation | 2 |
| 158 | aminooxygenation | 1 |
| 159 | tnp-haptenation | 1 |
| 160 | continuity/coordination | 1 |
| 161 | ru-contamination | 1 |
| 162 | dichloroimination | 1 |
| 163 | astatination | 1 |
| 164 | non-preparation | 1 |
| 165 | co-generation | 1 |
| 166 | reperforation | 1 |
| 167 | type/duration | 2 |
| 168 | follow-up/duration | 1 |
| 169 | fluidisation | 1 |
| 170 | distortion/defragmentation | 1 |
| 171 | presence/augmentation | 1 |
| 172 | bio-fermentation | 1 |
| 173 | overevaluation | 1 |
| 174 | privation | 1 |
| 175 | depolarization-induced-activation | 1 |
| 176 | vitalization | 2 |
| 177 | bromoaminocyclization | 1 |
| 178 | self-destabilization | 1 |
| 179 | scarring/reorganization | 1 |
| 180 | deionization | 1 |
| 181 | m1-/m2-polarization | 1 |
| 182 | overparameterization | 1 |
| 183 | codetection | 1 |
| 184 | rarefiction | 1 |
| 185 | initiation/extinction | 1 |
| 186 | nonsecretion | 1 |
| 187 | post-addition | 1 |
| 188 | event-prevention | 1 |
| 189 | structure/distribution | 1 |
| 190 | synthesis/breakdown | 1 |
| 191 | 26.7kbp | 1 |
| 192 | frostnip | 1 |
| 193 | γseop | 1 |
| 194 | 2000meq | 1 |
| 195 | time/number | 1 |
| 196 | type/number | 2 |
| 197 | levo-isomer | 1 |
| 198 | non-consumer | 1 |
| 199 | sunphotometer | 1 |
| 200 | themetaregister | 1 |
| 201 | catalyzer | 1 |
| 202 | non-expressor | 2 |
| 203 | receptor-activator | 1 |
| 204 | endo-factor | 1 |
| 205 | reversible-inhibitor | 1 |
| 206 | tissue-inhibitor | 1 |
| 207 | 3′-utr | 1 |
| 208 | micro-areas | 1 |
| 209 | hepatotoxicokinetics | 1 |
| 210 | 3incidences | 1 |
| 211 | ntelopeptides | 1 |
| 212 | d-efficiencies | 1 |
| 213 | six-compound-libraries | 1 |
| 214 | photostabilities | 1 |
| 215 | adcs-activities | 1 |
| 216 | 5-cycles | 1 |
| 217 | mirnaomes | 1 |
| 218 | sub-syndromes | 1 |
| 219 | 1-aryl-2-hydrazonoimidazolidines | 1 |
| 220 | driving-pressures | 1 |
| 221 | internet-databases | 3 |
| 222 | fixed-doses | 1 |
| 223 | subtrates | 1 |
| 224 | ofdiabetes | 1 |
| 225 | marites | 1 |
| 226 | lings | 1 |
| 227 | fine-mappings | 1 |
| 228 | resident-months | 1 |
| 229 | self-homeostasis | 1 |
| 230 | monoparesis | 1 |
| 231 | porokeratosis | 2 |
| 232 | ii-meta-analysis | 1 |
| 233 | cyclization/hydrolysis | 1 |
| 234 | ~4weeks | 1 |
| 235 | 36±3.9weeks | 1 |
| 236 | rootbarks | 1 |
| 237 | vels | 1 |
| 238 | sublevels | 1 |
| 239 | 24-recalls | 1 |
| 240 | shorter-terms | 1 |
| 241 | firestorms | 1 |
| 242 | ecg-signs | 1 |
| 243 | gallocatechins | 1 |
| 244 | commemorations | 1 |
| 245 | low-concentrations | 1 |
| 246 | modes/durations | 1 |
| 247 | sedimentations | 1 |
| 248 | systematizations | 1 |
| 249 | clinicians'perceptions | 1 |
| 250 | 3688.15tons | 1 |
| 251 | 6-18years | 2 |
| 252 | midsummers | 1 |
| 253 | d-enantiomers | 1 |
| 254 | world-wide.three-quarters | 1 |
| 255 | airrs | 1 |
| 256 | regardless | 5,186 |
| 257 | but-regardless | 1 |
| 258 | precision/vagueness | 1 |
| 259 | 'stiffness | 1 |
| 260 | floppiness | 1 |
| 261 | deficiency-weakness | 1 |
| 262 | sorness | 1 |
| 263 | raucousness | 1 |
| 264 | number/size/wetness | 1 |
| 265 | 'shortness | 2 |
| 266 | countess | 1 |
| 267 | supershifts | 1 |
| 268 | 'ingredients | 1 |
| 269 | gnments | 1 |
| 270 | key-points | 1 |
| 271 | acrts | 1 |
| 272 | pcr-tests | 1 |
| 273 | 'outbursts | 1 |
| 274 | 'locus | 1 |
| 275 | acrys | 1 |
| 276 | non-respect | 1 |
| 277 | re-conduct | 1 |
| 278 | sleight | 1 |
| 279 | “weight | 1 |
| 280 | onslaught | 1 |
| 281 | α1c-subunit | 1 |
| 282 | stimulant/depressant | 1 |
| 283 | 53percent | 1 |
| 284 | measurament | 1 |
| 285 | co-engagement | 1 |
| 286 | underinvolvement | 1 |
| 287 | efforts.improvement | 1 |
| 288 | embellishment | 1 |
| 289 | non-containment | 1 |
| 290 | non-attainment | 2 |
| 291 | performance-assessment | 1 |
| 292 | hospitalization/treatment | 1 |
| 293 | size/amount | 1 |
| 294 | linelist | 1 |
| 295 | follow-up.most | 1 |
| 296 | shaltout | 1 |
| 297 | non-adequacy | 2 |
| 298 | semiquantify | 1 |
| 299 | irrespectively | 33 |
| 300 | primarly | 1 |
| 301 | polyphyly | 1 |
| 302 | macroscopy | 3 |
| 303 | tory | 1 |
| 304 | mohltccourtesy | 1 |
| 305 | inefficacity | 1 |
| 306 | type/periodicity | 1 |
| 307 | hepatocyte-toxicity | 1 |
| 308 | veloycity | 1 |
| 309 | nonhomogeneity | 1 |
| 310 | fluxionality | 1 |
| 311 | relaxation/quality | 1 |
| 312 | h-permeability | 1 |
| 313 | quality/availability | 1 |
| 314 | duration/sustainability | 1 |
| 315 | distractability | 1 |
| 316 | acceptability•feasibility | 1 |
| 317 | inconformity | 1 |
| 318 | colority | 1 |
| 319 | sapienza-university | 1 |
| 320 | friedrich-schiller-university | 1 |
| 321 | humboldt-university | 1 |
| 322 | zimmer/university | 1 |
| 323 | nonnecessity | 1 |
| 324 | withsensitivity | 1 |
| 325 | aba-hypersensitivity | 1 |
| 326 | independenty | 1 |
| 327 | cytotoxicyty | 1 |
| 328 | cc₅₀ | 1 |
| 329 | ⅓ | 1 |